Connective Tissue and Related Disorders Panel Genetic Test in UAE | 3000 AED | DNA Labs UAE

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.

Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by a DHA-licensed Consultant Medical Geneticist.

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced Next-Generation Sequencing (NGS) panel analyzes 69 genes associated with hereditary connective tissue disorders including Ehlers-Danlos syndrome, Marfan syndrome, and related pathologies. The test provides comprehensive molecular diagnostic insights for patients presenting with clinical features suggestive of a connective tissue disorder, enabling precise variant detection and classification.

Feature	Connective Tissue NGS Panel (69 Genes)	Single‑Gene / Biochemical Assays
Precision	Multigene NGS – 99.9% analytical sensitivity across full coding regions	Limited to one or few genes; may miss atypical or multi‑gene variants
Methodology	NGS with complete coding region coverage, deletion/duplication analysis, and ACMG classification	Sanger sequencing or enzymatic biochemical assays
Turnaround Time	3–4 weeks from sample receipt to final report	4–8 weeks depending on stepwise testing cascade

Physician Insight & Safety Protocols

“As a Consultant Medical Geneticist, I emphasize that this comprehensive NGS panel enables precise molecular diagnosis for patients with clinical features suggestive of hereditary connective tissue disorders. However, results must always be interpreted within the full clinical context, including family history and physical examination findings. A pathogenic variant confirms a genetic predisposition, while a negative result does not definitively exclude all connective tissue pathologies. Open dialogue with your referring physician is essential before any medical decisions are made based on these findings.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory – Medication Continuation

⚠ Do not discontinue, adjust, or initiate any prescribed medication based solely on genetic test results without direct consultation with your treating physician. All clinical management decisions require integrated assessment of laboratory, imaging, and physical examination data.

Exclusion Criteria & Clinical Red Flags

Acute systemic illness or haemodynamic instability at the time of sample collection.
Inability to provide a blood sample or FTA card due to severe needle phobia or documented medical contraindication.
Non‑consenting minors without legal guardian approval (per UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability).
Known aortic root dilation >4.5 cm – urgent cardiology evaluation is required before proceeding with genetic testing.
Symptoms of acute vascular rupture (severe chest or abdominal pain, sudden dyspnoea) warrant immediate emergency care.

Patient FAQ & Clinical Guidance

1. What is the Connective Tissue and Related Disorders NGS Panel?

A: A comprehensive genetic test screening 69 genes linked to hereditary connective tissue pathologies such as Ehlers-Danlos syndrome, Marfan syndrome, and related disorders. It employs next‑generation sequencing to detect single nucleotide variants, small insertions/deletions, and copy number alterations, enabling precise molecular diagnosis for patients with clinical suspicion of a connective tissue disorder.

2. How is the sample collected and what are the requirements?

A: A standard peripheral whole blood draw or a single drop of blood on an FTA card is sufficient. VIP Mobile Phlebotomy and temperature‑controlled cold‑chain home collection are available daily from 8 AM to 11 PM. A detailed clinical history and a three‑generation pedigree chart are required for accurate interpretation; pre‑test genetic counselling is provided.

3. How long do results take and how reliable is the test?

A: Results are delivered within 3–4 weeks with 99.9% analytical sensitivity under ISO 9001:2015 accredited processes. The final report includes variant classification according to ACMG guidelines, followed by a telephonic post‑test clinical guidance session with a DHA‑licensed Consultant Medical Geneticist to discuss findings and recommendations.

UAE Regulatory & Data Privacy Adherence

Data Protection & Health Information Governance

All genetic data handling and patient information processing at DNA Labs UAE strictly complies with:

Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, storage, and transfer of personal data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating health data systems and electronic medical records.
Federal Decree‑Law No. 4 of 2016 on Medical Liability – ensuring patient consent, clinical safety, and professional accountability.

ISO 9001:2015 certified processes (Cert: INT/EGQ/2509DA/3139) underpin all laboratory operations. Results are communicated confidentially and are only released to the ordering physician or the patient upon verified consent.

Clinical & Logistical Metadata

Test Name	Connective Tissue and Related Disorders Panel (69 Genes) – NGS
Price (AED)	3,000 AED (Insurance direct billing available)
Turnaround Time	3–4 Weeks from sample receipt
Sample Type / Matrix	Whole Blood (EDTA), Extracted DNA, or One Drop Blood on FTA Card. VIP Mobile Phlebotomy & Cold‑Chain Home Collection is available daily from 8 AM to 11 PM.
Methodology Used	Next‑Generation Sequencing (NGS) with full coding region coverage, deletion/duplication analysis, and ACMG variant classification
ICD-10-CM Code	M35.9, Q79.6, Q87.4
LOINC Code	94757-6
DHA Facility License & Laboratory Address	License No: 1143 \| DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE